Despite the undisputed role of HER2-targeted therapy in HER2+ breast cancer, response to agents targeting HER2 with different molecular mechanisms displays intra- and inter-patient heterogeneity [5,6]. The gene discussed is ERBB2; the disease is breast carcinoma.